Website maintenance took place on Thursday 30 April 2026. If you experience any issues, please contact us.
Notice for nirogacestat hydrobromide (Merck Healthcare Pty Ltd)
Active ingredients
nirogacestat hydrobromide
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
tablet
Indication
For the treatment of desmoid tumours
Therapeutic area
Oncology